Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 4/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.34 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.34 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | SMO | Q99835 | 1/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL217146 | 0.78 | MAPT (0.52) | GAAL3MBTL1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL4775732 | 0.68 | NISCH (0.58) | GAAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL29466815 | 0.68 | NISCH (0.58) | GAAMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL217145 | 0.68 | SMN1; SMN2 (0.39) | MAPTSMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL216597 | 0.66 | MAPT (0.54) | GAAL3MBTL1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL4105577 | 0.64 | GAA (0.55) | GAAL3MBTL1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL214570 | 0.62 | GAA (0.55) | GAAL3MBTL1TDP1MAPTSMN1; SMN2 | |
| SCHEMBL29763579 | 0.60 | SMN1; SMN2 (0.66) | GAASMN1; SMN2MEN1KMT2AKDM4E | |
| SCHEMBL31429683 | 0.59 | NISCH (0.56) | L3MBTL1TDP1MAPTSMN1; SMN2MEN1 | |
| SCHEMBL2036971 | 0.59 | NISCH (0.56) | GAAMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | EXELIXIS, INC. (US) | 2010-06-03 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100136136-A1 | JAK-2 Modulators and Methods of Use | JAK2, JAK1, JAK3 | GAA 2375/4885L3MBTL1 3660/4885TDP1 3233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.